Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
Status:
Terminated
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of
anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia
in a dose-escalation way.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University